When to Initiate, When to Switch, and How to Sequence Hiv Therapies: a Markov Decision Process Approach
Year: 2006
Type: article
Abstract: HIV and AIDS are major health care problems throughout the world,with 40 million people living with HIV by the end of 2005. Inthat year alone, 5 million people acquired HIV, and 3 millionpeople died of AIDS. For many patients, advances in therapies overthe past ten years have changed HIV from a fatal disease to achronic, yet manageable condition. The purpose of thisdissertation is to address the challenge of effectively managingHIV therapies, with a goal of maximizing a patient's totalexpected lifetime or quality-adjusted lifetime.Perhaps the most important issue in HIV care is when a patientshould initiate therapy. Benefits of delaying therapy includeavoiding the negative side effects and toxicities associated withthe drugs, delaying selective pressures that induce thedevelopment of resistant strains of the virus, and preserving alimited number of treatment options. On the other hand, the risksof delayed therapy include the possibility of irreversible damageto the immune system, development of AIDS-related complications,and death. We develop a Markov decision process (MDP) model thatexamines this question, and we solve it using clinical data.Because of the development of resistance to administered therapiesover time, an extension to the initiation question arises: whenshould a patient switch therapies? Also, inherent in both theinitiation and switching questions is the question of whichtherapy to use each time. We develop MDP models that consider theswitching and sequencing problems, and we discuss the challengesinvolved in solving these models.
Author: Steven M. Shechter
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2168336417